Molecular Drug Targets in Myeloproliferative Neoplasms: Mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1

Journal of Cellular and Molecular Medicine - United Kingdom
doi 10.1111/j.1582-4934.2008.00559.x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

JAK2 and MPL Mutations in Myeloproliferative Neoplasms: Discovery and Science

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

JAK2, CALR, and MPL Mutation Spectrum in Japanese Patients With Myeloproliferative Neoplasms

Haematologica
Hematology
2014English

MPL W515 L/K Mutations in Myeloproliferative Neoplasms

Egyptian Journal of Medical Human Genetics
Genetics
2019English

JAK2 Exon 14 Deletion in Patients With Chronic Myeloproliferative Neoplasms

PLoS ONE
Multidisciplinary
2010English

Characterization of CD34+ Hematopoietic Progenitor Cells in JAK2 V617F and CALR -Mutated Myeloproliferative Neoplasms

Leukemia Research
Cancer ResearchOncologyHematology
2016English

Current Pre-Clinical and Clinical Advances in the BCR-ABL1-positive and -Negative Chronic Myeloproliferative Neoplasms

Haematologica
Hematology
2014English

Role of Mesenchymal Stromal Cells and Their Extracellular Vesicles microRNAs in JAK2 Myeloproliferative Neoplasms

English

The Role of the JAK2 GGCC Haplotype and the TET2 Gene in Familial Myeloproliferative Neoplasms

Haematologica
Hematology
2010English

Positive Immunohistochemical Staining of KIT in Solid-Pseudopapillary Neoplasms of the Pancreas Is Not Associated With KIT/PDGFRA Mutations

Modern Pathology
Forensic MedicinePathology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy